Diagnosing the decline in pharmaceutical R&D efficiency.
about
The genome and transcriptome of the zoonotic hookworm Ancylostoma ceylanicum identify infection-specific gene familiesDiscovery and resupply of pharmacologically active plant-derived natural products: A reviewResearch Funding: the Case for a Modified LotteryWhen Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisEvidence-Based Medicine as a Tool for Undergraduate Probability and Statistics EducationIncreasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical researchManaging risks in drug discovery: reproducibility of published findingsA safe lithium mimetic for bipolar disorderAdapting Drug Approval Pathways for Bacteriophage-Based TherapeuticsChanging R&D; models in research-based pharmaceutical companiesMicrofluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering.Bygiene: The New Paradigm of Bidirectional HygieneEngineering large animal models of human diseaseNanotheranostics for personalized medicinePatient representatives' contributions to the benefit-risk assessment tasks of the European Medicines Agency scientific committeesOpen Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseClinical studies in lysosomal storage diseases: Past, present, and futureSystematic, spatial imaging of large multimolecular assemblies and the emerging principles of supramolecular order in biological systems.Improving the predictive value of interventional animal models dataMetabolomics and systems pharmacology: why and how to model the human metabolic network for drug discoveryμOrgano: A Lego®-Like Plug & Play System for Modular Multi-Organ-ChipsFacilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnershipsZebrafish small molecule screens: Taking the phenotypic plungeOpportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big DataCombination therapeutics in complex diseasesThe promises of quantitative systems pharmacology modelling for drug developmentImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysAccelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screeningUtility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological DisordersInduced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous SystemOrgans-on-chips at the frontiers of drug discoveryFuture technology insight: mass spectrometry imaging as a tool in drug research and development.An overview of the synthetic routes to the best selling drugs containing 6-membered heterocyclesBiosimilars: company strategies to capture value from the biologics marketTracking 20 years of compound-to-target output from literature and patentsKnowledge-based fragment binding predictionSurveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal GenomicsCANDO and the infinite drug discovery frontier
P2860
Q22122063-965947C5-C33C-40C0-883E-D173EFBB2B60Q22252341-89ADA08A-3864-448C-945E-5A1EBF7CC6B7Q24048946-28EC4240-E21F-46FC-BFEA-9E2691CB6A71Q24288687-4139B5FC-E9B2-487C-B515-FD0D0EC7A67CQ24288834-C1F09375-5719-42BD-884A-CA2B581BFED1Q24289253-AA1F28A7-325A-41DA-9358-C7E4822B8B67Q24289508-EEBE4566-C611-49AB-BEB1-7EFE9DC85A94Q24600175-6DB39373-89E2-44EE-B726-AD7EE9BBA93AQ26740597-EA76D600-7FF5-403B-B4D6-51F0BD796123Q26749511-C0BE7767-8571-4F45-BEDC-7EFE280F67FDQ26774240-590F3BFB-4BFE-4753-B7F0-E24AAE19D9ADQ26775819-7D29A8A8-959A-4267-A902-392227C5C631Q26785547-BEB66254-456A-4637-BDC8-C30BB995B023Q26851449-A0DD028A-2EA0-4322-8598-11CCE1471581Q26866292-20A92589-D066-45D2-96AA-8AB4E6DD17CAQ26883657-1288A23C-65D4-451A-A2D2-51531EEBE460Q27008867-C204CF06-0EFF-40DD-803C-215504202386Q27024122-40F98442-D989-4D61-B106-5CE8CC7FC372Q27025186-C907004F-7EA1-4650-81D4-16A308F36088Q27026607-8454509B-0C39-4086-ADCE-E8B1BC67EC25Q27026822-A7C843C5-D6B4-473E-9079-C22E32D1A78CQ27144251-8F920E84-08D8-45E4-8B9A-8B8999B699FBQ27315172-6C1D4A66-6B1C-4E7D-A444-2B10C0581333Q28069462-C8D156EB-EAE1-4AC1-ABD9-1F78CFC94DB9Q28073655-52322D47-4102-47DE-811C-426B07ECB967Q28076506-D405590A-6947-4777-9F2D-FC079B4F8370Q28076891-823700FA-E82E-43AB-9171-C557B5EB2239Q28077650-FAEDE428-E3A2-474C-922B-90DE1809E5FCQ28077848-D35D3D68-44FC-4C00-AFF8-909107E4A5ACQ28080068-6BDDAD3B-FFBF-48B1-8C3D-DFE6B2F8F0FAQ28080219-0CD069F5-3060-4C21-82A8-A7AAE4610401Q28082668-0028A2C8-7850-4F15-A2EC-B06A0F4F4BB7Q28083671-6F3129F2-016B-40B5-816C-0C7B627504FEQ28087460-F3853586-1F01-4B18-838F-EEE7A1A868E9Q28301501-426CA091-02C5-4148-A802-9B146379E51DQ28302861-39E82DAD-4251-48B6-9045-90561D306FECQ28534695-39F748D9-5B6E-42D2-9D4C-E9D37BF86716Q28538204-9EFA32DD-A389-42A1-8476-67BA0D180EACQ28542977-7CAA730D-C050-4C69-95C0-692687938103Q28543019-D4A7FA3E-7004-4184-961F-60F5F8C4BD88
P2860
Diagnosing the decline in pharmaceutical R&D efficiency.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Diagnosing the decline in pharmaceutical R&D efficiency.
@ast
Diagnosing the decline in pharmaceutical R&D efficiency.
@en
Diagnosing the decline in pharmaceutical R&D efficiency.
@nl
type
label
Diagnosing the decline in pharmaceutical R&D efficiency.
@ast
Diagnosing the decline in pharmaceutical R&D efficiency.
@en
Diagnosing the decline in pharmaceutical R&D efficiency.
@nl
prefLabel
Diagnosing the decline in pharmaceutical R&D efficiency.
@ast
Diagnosing the decline in pharmaceutical R&D efficiency.
@en
Diagnosing the decline in pharmaceutical R&D efficiency.
@nl
P2093
P356
P1476
Diagnosing the decline in pharmaceutical R&D efficiency.
@en
P2093
Alex Blanckley
Brian Warrington
Helen Boldon
Jack W Scannell
P2888
P304
P356
10.1038/NRD3681
P577
2012-03-01T00:00:00Z